Zura Bio discontinues tibulizumab in HS after Phase II trial failure
Zura Bio has discontinued the clinical development of tibulizumab in HS after the Phase II TibuSHIELD trial failed to meet its endpoints.
The post Zura Bio discontinues tibulizumab in HS after Phase II trial failure appeared first on Clinical Trials Arena .